Dr Audrey Hime, MD | |
100 Moccasin Bend Rd, Chattanooga, TN 37405-4415 | |
(423) 265-2271 | |
Not Available |
Full Name | Dr Audrey Hime |
---|---|
Gender | Female |
Speciality | Psychiatry & Neurology - Psychiatry |
Location | 100 Moccasin Bend Rd, Chattanooga, Tennessee |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437425949 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | MD0000054253 (Tennessee) | Primary |
2084P0800X | Psychiatry & Neurology - Psychiatry | 25977 (West Virginia) | Secondary |
Entity Name | State Of Tennessee |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487791315 PECOS PAC ID: 5698687077 Enrollment ID: O20031104000309 |
News Archive
The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.
During the WHO's 63rd Regional Committee Session for South-East Asia in Bangkok on Wednesday the WHO called for enhanced "efforts at the national and international level to preserve the efficacy of antimicrobial agents through the rational use of antibiotics," Indian Express reports (Thacker, 9/9).
POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications (ANDAs) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic copies of Treximet.
A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe.
A team of cancer researchers at the University of California, San Diego has identified the existence of precursor cells in early prostate cancers. These cells are resistant to androgen-deprivation therapy, and may drive the subsequent emergence of recurrent or metastatic prostate cancer.
› Verified 6 days ago
Entity Name | Revitalist Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1073168241 PECOS PAC ID: 6800295650 Enrollment ID: O20210527000088 |
News Archive
The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.
During the WHO's 63rd Regional Committee Session for South-East Asia in Bangkok on Wednesday the WHO called for enhanced "efforts at the national and international level to preserve the efficacy of antimicrobial agents through the rational use of antibiotics," Indian Express reports (Thacker, 9/9).
POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications (ANDAs) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic copies of Treximet.
A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe.
A team of cancer researchers at the University of California, San Diego has identified the existence of precursor cells in early prostate cancers. These cells are resistant to androgen-deprivation therapy, and may drive the subsequent emergence of recurrent or metastatic prostate cancer.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Audrey Hime, MD 100 Moccasin Bend Rd, Chattanooga, TN 37405-4415 Ph: () - | Dr Audrey Hime, MD 100 Moccasin Bend Rd, Chattanooga, TN 37405-4415 Ph: (423) 265-2271 |
News Archive
The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.
During the WHO's 63rd Regional Committee Session for South-East Asia in Bangkok on Wednesday the WHO called for enhanced "efforts at the national and international level to preserve the efficacy of antimicrobial agents through the rational use of antibiotics," Indian Express reports (Thacker, 9/9).
POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that the United States District Court for the Eastern District of Texas has issued a favorable verdict in the litigation between POZEN and several generic pharmaceutical companies which had filed Abbreviated New Drug Applications (ANDAs) seeking approval from the U.S. Food and Drug Administration (FDA) to market generic copies of Treximet.
A landmark study published in the New England Journal of Medicine today heralds a new era in stroke treatment across the globe.
A team of cancer researchers at the University of California, San Diego has identified the existence of precursor cells in early prostate cancers. These cells are resistant to androgen-deprivation therapy, and may drive the subsequent emergence of recurrent or metastatic prostate cancer.
› Verified 6 days ago
Chelsea Amanda Shugars, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 979 East 3rd Street, Suite C-830, Chattanooga, TN 37403 Phone: 423-778-9001 Fax: 423-778-4692 | |
Dr. George Michael Schmits, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1 Northgate Park, Suite 201, Chattanooga, TN 37415 Phone: 423-870-5647 | |
Alexia Flangini, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 900 E 3rd St, Chattanooga, TN 37403 Phone: 423-778-5437 Fax: 423-778-7507 | |
James H Broom, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 420 Bell Ave, Chattanooga, TN 37405 Phone: 423-756-2740 Fax: 423-756-4854 | |
Dr. Yuchun Han, M.D. & PH.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1626 Gunbarrel Rd, Chattanooga, TN 37421 Phone: 423-698-8747 Fax: 423-698-8847 | |
Hytham A Kadrie, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 721 Glenwood Dr, Ste 467-west, Chattanooga, TN 37404 Phone: 423-698-3423 Fax: 423-698-1380 | |
Sharon Nancy Farber, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 513 Dodds Ave Ste 103, Chattanooga, TN 37404 Phone: 423-698-3423 Fax: 423-698-1380 |